Ivonescimab (Not yet branded)

Description

Ivonescimab is a bispecific antibody that simultaneously targets both PD-1 and VEGF pathways for the treatment of metastatic colorectal cancer. This dual-targeting immunotherapy agent is being evaluated in combination with standard chemotherapy regimens like FOLFOX and CAPOX for patients with both microsatellite stable (MSS) and microsatellite instability-high (MSI-H) colorectal cancers. The drug shows promise in treating initially unresectable colorectal cancer liver metastases and locally advanced rectal cancer when combined with chemotherapy and radiation therapy.

Mechanism of Action

Ivonescimab functions as a bispecific antibody that blocks both the PD-1 immune checkpoint pathway and VEGF-mediated angiogenesis simultaneously. By inhibiting PD-1, it enhances T-cell activation and anti-tumor immune responses, while VEGF blockade reduces tumor blood vessel formation and growth. This dual mechanism combines immunotherapy with anti-angiogenic effects to potentially improve treatment outcomes compared to single-pathway targeting.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials